China Approves 59 Innovative Drugs So Far This Year

The ratio of novel-mechanism approvals to total approvals is the more telling figure here than the headline count, since it speaks to whether domestic R&D is moving beyond fast-follow programs. The disclosed deal value across the first eight months points to licensing and partnership activity running at a scale that now matters to global pharma dealflow, not just to China's domestic market. Whether that deal pace holds, and whether the novel-target share keeps climbing, is the open question for anyone tracking cross-border biopharma capital.